{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:18:42Z","timestamp":1784791122051,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00108-026-02130-4","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:18:10Z","timestamp":1780910290000},"page":"882-891","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Amyloidosen \u2013 Klassifikation, Diagnostik und Therapie","Amyloidosis: classification, diagnosis, and treatment"],"prefix":"10.1007","volume":"67","author":[{"given":"Kiavasch M. N.","family":"Farid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sch\u00f6nland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"aus dem Siepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Weiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Beimler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"2130_CR1","doi-asserted-by":"publisher","unstructured":"Buxbaum JN, Dispenzieri A, Eisenberg DS, et\u00a0al. Amyloid. 2022 https:\/\/doi.org\/10.1080\/13506129.2022. 2147636.","DOI":"10.1080\/13506129.2022"},{"key":"2130_CR2","doi-asserted-by":"publisher","unstructured":"Hegenbart U, aus dem Siepen F, Carpinteiro A et\u00a0al. 2024; 31 (Suppl.1): S1\u2013S245. https:\/\/doi.org\/10.1080\/13506129.2024.2347124","DOI":"10.1080\/13506129.2024.2347124"},{"key":"2130_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.08.041","author":"RA Kyle","year":"2019","unstructured":"Kyle\u00a0RA, Larson\u00a0DR, Kurtin\u00a0PJ et\u00a0al (2019) Mayo Clin Proc. https:\/\/doi.org\/10.1016\/j.mayocp.2018.08.041","journal-title":"Mayo Clin Proc"},{"key":"2130_CR4","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.859","author":"RA Kyle","year":"2004","unstructured":"Kyle\u00a0RA, Therneau\u00a0TM, Rajkumar\u00a0SV, Larson\u00a0DR, Plevak\u00a0MF, Melton\u00a0LJ (2004) Mayo Clin Proc. https:\/\/doi.org\/10.4065\/79.7.859","journal-title":"Mayo Clin Proc"},{"key":"2130_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2016.1207626","author":"MA Aguirre","year":"2016","unstructured":"Aguirre\u00a0MA, Boietti\u00a0BR, Nucifora\u00a0E et\u00a0al (2016) Amyloid. https:\/\/doi.org\/10.1080\/13506129.2016.1207626","journal-title":"Amyloid"},{"key":"2130_CR6","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399402004647","author":"MJM Saraiva","year":"2002","unstructured":"Saraiva\u00a0MJM (2002) Expert Rev Mol Med. https:\/\/doi.org\/10.1017\/S1462399402004647","journal-title":"Expert Rev Mol Med"},{"issue":"1","key":"2130_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/13506129.2018.1429391","volume":"25","author":"N Blank","year":"2018","unstructured":"Blank\u00a0N, Hegenbart\u00a0U, Dietrich\u00a0S et\u00a0al (2018) Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. Amyloid 25(1):37\u201345. https:\/\/doi.org\/10.1080\/13506129.2018.1429391","journal-title":"Amyloid"},{"key":"2130_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02558","author":"J Khwaja","year":"2026","unstructured":"Khwaja\u00a0J, Kirkwood\u00a0AA, Milani\u00a0P et\u00a0al (2026) J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/JCO-25-02558","journal-title":"J Clin Oncol"},{"key":"2130_CR9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024623","author":"E Muchtar","year":"2024","unstructured":"Muchtar\u00a0E, Geyer\u00a0S, Merlini\u00a0G, Gertz\u00a0MA (2024) Blood. https:\/\/doi.org\/10.1182\/blood.2024024623","journal-title":"Blood"},{"key":"2130_CR10","unstructured":"Onkopedia-Leitlinie Amyloidose (Leichtketten (AL) \u2013 Amyloidose) (2025) Onkopedia-Leitlinie Amyloidose (Leichtketten (AL) \u2013 Amyloidose). onkopedia.com\/de\/onkopedia\/guidelines\/amyloidose-leichtketten-al-amyloidose. Accessed 18.2.2026"},{"key":"2130_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.033","author":"M Grogan","year":"2016","unstructured":"Grogan\u00a0M, Scott\u00a0CG, Kyle\u00a0RA et\u00a0al (2016) J\u00a0Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.033","journal-title":"J Am Coll Cardiol"},{"key":"2130_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070265","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann\u00a0HJ, Goodman\u00a0HJB, Gilbertson\u00a0JA et\u00a0al (2007) N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa070265","journal-title":"N Engl J Med"},{"key":"2130_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028631","author":"E Kastritis","year":"2021","unstructured":"Kastritis\u00a0E, Palladini\u00a0G, Minnema\u00a0MC et\u00a0al (2021) N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2028631","journal-title":"N Engl J Med"},{"key":"2130_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25915","author":"M Basset","year":"2020","unstructured":"Basset\u00a0M, Hummedah\u00a0K, Kimmich\u00a0C et\u00a0al (2020) Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.25915","journal-title":"Am J Hematol"},{"key":"2130_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510209","author":"JD Gillmore","year":"2025","unstructured":"Gillmore\u00a0JD, Gane\u00a0E, T\u00e4ubel\u00a0J et\u00a0al (2025) N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2510209","journal-title":"N Engl J Med"},{"key":"2130_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225114","author":"P Kvacskay","year":"2024","unstructured":"Kvacskay\u00a0P, Hegenbart\u00a0U, Lorenz\u00a0HM, Sch\u00f6nland\u00a0SO, Blank\u00a0N (2024) Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2023-225114","journal-title":"Ann Rheum Dis"},{"key":"2130_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.03.429","author":"A Porcari","year":"2024","unstructured":"Porcari\u00a0A, Cappelli\u00a0F, Nitsche\u00a0C et\u00a0al (2024) J\u00a0Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.429","journal-title":"J Am Coll Cardiol"},{"key":"2130_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2025.2463678","author":"E Muchtar","year":"2025","unstructured":"Muchtar\u00a0E, Grogan\u00a0M, aus dem Siepen\u00a0F et\u00a0al (2025) Amyloid. https:\/\/doi.org\/10.1080\/13506129.2025.2463678","journal-title":"Amyloid"},{"key":"2130_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2024.06.009","author":"FM Lang","year":"2024","unstructured":"Lang\u00a0FM, Teruya\u00a0S, Cuomo\u00a0M et\u00a0al (2024) J\u00a0Card Fail. https:\/\/doi.org\/10.1016\/j.cardfail.2024.06.009","journal-title":"J Card Fail"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02130-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02130-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02130-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:53:25Z","timestamp":1784789605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02130-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2130"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02130-4","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.M.N.\u00a0Farid\n                      : A.\u00a0Finanzielle Interessen: Pierre Fabre: Reisekosten f\u00fcr wissenschaftliche Meetings (nicht in Bezug auf Amyloidose), Kite\/Gilead: Reisekosten f\u00fcr wissenschaftliche Meetings (nicht in Bezug auf Amyloidose). \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Arzt in Weiterbildung, Medizinische Klinik\u00a0V (H\u00e4matologie).\n                      S.\u00a0Sch\u00f6nland\n                      : A.\u00a0Finanzielle Interessen: Neurimmune, wissenschaftliche Zusammenarbeit Therapie AL-Amyloidose; Protego, wissenschaftliche Zusammenarbeit Therapie AL-Amyloidose; Alexion, wissenschaftliche Zusammenarbeit Therapie AL-Amyloidose.\u00a0\u2013 Janssen, Referentent\u00e4tigkeiten und Advisory Board; Alexion, Advisory Board und Reisekostenerstattung zu Kongress; Prothena, Referentent\u00e4tigkeit, Advisory Board und Reisekostenerstattung zu Kongress; Pfizer, Referentent\u00e4tigkeit. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Oberarzt, Universit\u00e4tsklinikum Heidelberg | Herausgeber der Zeitschrift\n                      Amyloid\n                      , Past President International Society of Amyloidosis (ISA), Past President Deutsche Gesellschaft f\u00fcr Amyloiderkrankungen (DGAK).\n                      N.\u00a0Blank\n                      : A.\u00a0Finanzielle Interessen: SOBI und Novartis: Forschungsf\u00f6rderung.\u00a0\u2013 SOBI und Novartis: Unterst\u00fctzung Kongressteilnahme. \u2013\u00a0SOBI und Novartis: Vortragshonorare.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Internist und Rheumatologe, Universit\u00e4tsklinikum Heidelberg | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Rheumatologie (DGRh), Arbeitskreis Amyloidose.\n                      F.\u00a0aus dem Siepen\n                      : A.\u00a0Finanzielle Interessen: Vortragshonorare von Bayer, Alnylam, Pfizer und Alexion. \u2013\u00a0Beraterhonorare (Advisory Boards) von Bayer, Neurimmune, Pfizer.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte:r Internist, Klinik f\u00fcr Innere Medizin\u00a0III, Universit\u00e4tsklinikum Heidelberg | Mitgliedschaften: in der internationalen (ISA) und deutschen (DGAK) Fachgesellschaft f\u00fcr Amyloidoseerkrankungen.\n                      M.\u00a0Weiler\n                      : A.\u00a0Finanzielle Interessen: Referentenhonorare von Akcea Therapeutics, Alnylam Pharmaceuticals, AstraZeneca und Biogen. | Finanzielle Unterst\u00fctzung f\u00fcr Kongressteilnahmen von Akcea Therapeutics, Alnylam Pharmaceuticals, AstraZeneca, BridgeBio, Hoffmann-La Roche, Ionis und Pfizer. \u2013\u00a0Beraterhonorare von Akcea Therapeutics, Alnylam Pharmaceuticals, Biogen, F.\u00a0Hoffmann-La Roche, Novartis, Novo Nordisk, Pfizer, Purpose Pharma und Swedish Orphan Biovitrum AB; Referentenhonorare von Akcea Therapeutics, Alnylam Pharmaceuticals, AstraZeneca und Biogen; finanzielle Unterst\u00fctzung f\u00fcr Kongressteilnahmen von Akcea Therapeutics, Alnylam Pharmaceuticals, AstraZeneca, BridgeBio, F.\u00a0Hoffmann-La Roche, Ionis und Pfizer.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Neurologe: Neurologische Klinik, Universit\u00e4tsklinikum Heidelberg, Im Neuenheimer Feld\u00a0400, 69120\u00a0Heidelberg, Deutschland | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Neurologie (DGN), Deutsche Gesellschaft f\u00fcr Klinische Neurophysiologie (DGKN), DGAK, ISA, Deutsche Gesellschaft f\u00fcr Muskelkranke (DGM), Deutsche Gesellschaft f\u00fcr Liquordiagnostik und Klinische Neurochemie (DGLN).\n                      J.\u00a0Beimler\n                      : A.\u00a0Finanzielle Interessen: J.\u00a0Beimler gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Mitarbeiter Nierenzentrum Heidelberg.\n                      U.\u00a0Hegenbart\n                      : A.\u00a0Finanzielle Interessen: Janssen, Unterst\u00fctzung f\u00fcr Forschungsaktivit\u00e4ten, Amyloidose-Register; Neurimmune AG, wissenschaftliche Zusammenarbeit, Therapietargets.\u00a0\u2013 AstraZeneca, Beratert\u00e4tigkeit; Janssen, Beratert\u00e4tigkeit; Alnylam Germany GmbH, Referentent\u00e4tigkeit; Prothena, Beratert\u00e4tigkeit; Bayer Vital GmbH, Referentent\u00e4tigkeit. \u2013\u00a0Alexion, Nationales Advisory Board Amyloidose; Alnylam, Education Steering Committee.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Ober\u00e4rztin, Amyloidose-Zentrum, Universit\u00e4tsklinikum Heidelberg | Sprecherin des Amyloidose-Zentrums; stellvertretende Sprecherin, Vorstand des Zentrums f\u00fcr Seltene Erkrankungen, Heidelberg | Mitgliedschaft: DGAK","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}